2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vomiting
37
Nausea
25
Neoplasms
12
Breast Neoplasms
6
Lymphoma
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Rectal Neoplasms
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Leukemia
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Breast Neoplasms, Male
2
Weight Loss
1
Solid Tumors
1
Sarcoma
1
Radiation Injuries
1
Pancreatic Neoplasms
1
Pain
1
Neoplasms, Germ Cell and Embryonal
1
Nausea With Vomiting Chemotherapy-Induced
1
Melanoma
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Inflammatory Breast Neoplasms
1
Hematologic Diseases
1
Glioma
1
Interventions
Carboplatin
5
Paclitaxel
4
pembrolizumab
3
Educational Status
3
niraparib
2
anlotinib
2
Therapeutic Touch
2
Surveys and Questionnaires
2
Standard of Care
2
Radiotherapy
2
Pemetrexed
2
Palliative Care
2
Nivolumab
2
Methods
2
Interviews as Topic
2
Gemcitabine
2
Early Intervention, Educational
2
Bevacizumab
2
temsirolimus
1
rucaparib
1
relacorilant
1
olaparib
1
nintedanib
1
nilotinib
1
liposomal doxorubicin
1
lenvatinib
1
fosaprepitant
1
atezolizumab
1
argatroban
1
Watchful Waiting
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genital Neoplasms, Female
×
Palonosetron
×
Clear all
NCT01074697
2015-04-24
GAND-emesis
Odense University Hospital
Phase 3
Completed
246 enrolled